Nuvisan works on historically challenging targets such as transcription factors, scaffolding proteins and epigenetic regulators. We combine a structurally diverse compound and fragment library with advanced screening technologies, supported by in silico modelling and structure-based design, to identify binders for both the protein of interest (POI) and suitable E3 ligases. This supports targeting of both orthosteric and allosteric sites and provides strong starting points for PROTAC discovery.
Our experience in hit and lead discovery, together with optimisation in both rule-of-5 (Ro5) and beyond-rule-of-5 (bRo5) chemical space, supports candidate progression towards key project milestones. AI-guided ligand discovery, rational linker design and synthetic optimisation further support cellular and in vivo performance.
